Barry Ticho Sells 1,461 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 1,461 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $29.99, for a total transaction of $43,815.39. Following the transaction, the insider owned 40,702 shares in the company, valued at $1,220,652.98. This represents a 3.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Barry Ticho also recently made the following trade(s):

• On Wednesday, March 18th, Barry Ticho sold 6,686 shares of Stoke Therapeutics stock. The stock was sold at an average price of $31.34, for a total value of $209,539.24.
• On Tuesday, March 17th, Barry Ticho sold 6,164 shares of Stoke Therapeutics stock. The stock was sold at an average price of $33.01, for a total value of $203,473.64.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK opened at $33.51 on Friday. Stoke Therapeutics, Inc. has a 1 year low of $5.35 and a 1 year high of $40.22. The firm has a market cap of $1.98 billion, a P/E ratio of 50.01 and a beta of 1.07. The stock has a fifty day moving average price of $32.61 and a two-hundred day moving average price of $30.02.

Wall Street Analyst Weigh In

STOK has been the topic of a number of research analyst reports. BTIG Research reaffirmed a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a report on Thursday. Guggenheim started coverage on shares of Stoke Therapeutics in a report on Thursday, February 5th. They issued a “buy” rating and a $60.00 price target for the company. Chardan Capital restated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. Wall Street Zen cut shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Wolfe Research started coverage on shares of Stoke Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $40.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $41.83.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Janus Henderson Group PLC lifted its stake in Stoke Therapeutics by 333.8% in the 4th quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock worth $46,031,000 after acquiring an additional 1,116,452 shares in the last quarter. State Street Corp boosted its position in Stoke Therapeutics by 75.2% during the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after acquiring an additional 1,072,176 shares during the period. Corient Private Wealth LLC purchased a new position in Stoke Therapeutics during the 2nd quarter valued at about $7,489,000. BVF Inc. IL grew its stake in Stoke Therapeutics by 36.7% during the 4th quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock valued at $71,912,000 after acquiring an additional 608,578 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Stoke Therapeutics by 438.2% in the 3rd quarter. Wellington Management Group LLP now owns 737,753 shares of the company’s stock valued at $17,337,000 after purchasing an additional 600,687 shares during the period.

Key Stories Impacting Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.